text: Vibativ is not covered by HealthPartners for outpatient use.
  Vibativ is not covered for outpatient use as it offers little or no clinical advantages over current therapy and has safety concerns.
  Vibativ (telavancin) is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria:
  Complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S.constellatus), or Enterococcus faecalis (vancomycin-susceptible isolates only). and
  Hospital-acquired and ventilator-associated bacterial pneumonia, caused by susceptible isolates of Staphylococcus aureus (including methicillin-susceptible and –resistant isolates). VIBATIV should be reserved for use when alternative treatments are not suitable.
  Avoid use of Vibativ during pregnancy unless potential benefit to the patient outweighs the potential risk to the fetus. Adverse developmental outcomes observed in 3 animal species at clinically relevant doses raise concerns about potential adverse developmental outcomes in humans.
  Nephrotoxicity (either new onset or worsening) has occurred with use. Decreased efficacy is observed in moderate/severe baseline renal impairment (CrCl ≤ 50 mL/min).
  62847000101
  750mg single use vial
  Approved Medical Director Committee 7/1/11; Annual Review 7/2012, 7/2013, 7/2014, 11/2015,
  11/2016, 11/2017.
  Vibativ Prescribing Information. Theravance, Inc. South San Francisco, CA. May 2016.
  Telavancin (Vibativ) FDA Review Summary.
  http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist (Accessed 10/22/10)